sr141716 has been researched along with Parkinsonian Disorders in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, DY; Choi, DK; Kim, B; Ko, HM; Park, JY; Yoon, SH | 1 |
| Aley-Medina, P; Anaya-Martínez, V; Avila-Costa, MR; Espinosa-Villanueva, J; García-Ruiz, R; Gutiérrez-Valdez, AL; Montiel-Flores, E; Reynoso-Erazo, L; Sánchez-Betancourt, J; Torres-Esquivel, C; Tron-Alvarez, R | 1 |
| Armentero, MT; Baqi, Y; Bonaventura, J; Canela, EI; Casadó, V; Cortés, A; Costa, G; Farré, D; Franco, R; Lanciego, JL; Lluís, C; Mallol, J; Martínez-Pinilla, E; McCormick, P; Müller, CE; Pinna, A; Sánchez, M; Simola, N | 1 |
| Dowd, E; Finn, DP; Gorman, AM; Walsh, S | 1 |
| Caraballo, I; El-Banoua, F; Fernandez-Espejo, E; Flores, JA; Galan-Rodriguez, B | 1 |
| Caraballo, I; de Fonseca, FR; El Banoua, F; Fernandez-Espejo, E; Ferrer, B; Flores, JA; Galan-Rodriguez, B | 1 |
| Fernández-Ruiz, J; Ferraro, L; García-Arencibia, M; Tanganelli, S | 1 |
| Bisogno, T; Brotchie, JM; Crossman, AR; Di Marzo, V; Hill, MP | 1 |
8 other study(ies) available for sr141716 and Parkinsonian Disorders
| Article | Year |
|---|---|
2-(5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-N-(2-hydroxyethyl)-2-oxoacetamide (CDMPO) has anti-inflammatory properties in microglial cells and prevents neuronal and behavioral deficits in MPTP mouse model of Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents; Cannabinoid Receptor Antagonists; Cell Line; Dose-Response Relationship, Drug; Inflammation Mediators; Locomotion; Male; Mice; Mice, Inbred C57BL; Microglia; Parkinsonian Disorders; Rimonabant | 2020 |
The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Administration, Oral; Animals; Cannabinoid Receptor Antagonists; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Male; Nerve Degeneration; Neuropil; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rimonabant; Substantia Nigra; Tyrosine 3-Monooxygenase | 2013 |
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Cannabinoid Receptor Antagonists; Cholinesterase Inhibitors; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Rimonabant; Tacrine; Time Factors; Tremor | 2014 |
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dronabinol; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model.
Topics: Animals; Disease Models, Animal; Globus Pallidus; Male; Microinjections; Motor Activity; Neostriatum; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptors, Dopamine D1; Receptors, Dopamine D2; Rimonabant; Subthalamic Nucleus | 2004 |
Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Cannabinoids; Dose-Response Relationship, Drug; Male; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Substantia Nigra | 2005 |
Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats.
Topics: Animals; Corpus Striatum; Dose-Response Relationship, Drug; Drug Resistance; Extracellular Fluid; Glutamic Acid; Male; Microdialysis; Neural Inhibition; Oxidopamine; Parkinsonian Disorders; Piperidines; Presynaptic Terminals; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Sympatholytics; Synaptic Transmission; Up-Regulation | 2008 |
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
Topics: Animals; Arachidonic Acids; Benzazepines; Cannabinoid Receptor Modulators; Cannabinoids; Dopamine Agonists; Endocannabinoids; Globus Pallidus; Glycerides; Humans; Male; Motor Activity; Parkinsonian Disorders; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Reserpine; Rimonabant; Substantia Nigra; Tissue Distribution | 2000 |